Surgical Strategies for Locoregional Breast Cancer – De-Escalation

Here’s a breakdown of‍ the factors Dr. King considers when deciding on treatment de-escalation for patients with locoregional breast cancer,based on the provided text:

1. Molecular Subtype of Breast cancer: This is the primary driver of the decision.

HER2-positive: Excellent ‍candidates for preoperative chemotherapy. There’s a high likelihood (70-80%) ⁢the nodal‍ disease will be eradicated, allowing for de-escalation of axillary surgery (avoiding complete lymph node dissection).
HR-positive: Preoperative chemotherapy is less effective at downstaging (20-25% clearance rate). These patients‍ are more likely to still need a complete lymph node dissection even after preoperative therapy.

2. Extent of Nodal Involvement (Preoperative Assessment):

Limited nodal Involvement‍ (e.g., 1 abnormal lymph ‍node): Even in HR-positive ⁢cases, if only one node appears⁣ abnormal, proceeding directly to sentinel lymph node staging is considered.
Number of⁢ Positive Sentinel Nodes: If sentinel lymph node biopsy reveals⁢ only ⁢1 or 2 positive nodes, the patient might potentially be able to avoid a full axillary lymph node dissection, especially with⁤ planned ⁢postoperative systemic therapy and radiation.

3. Clinical Presentation:

Clinically ‍Node Negative: ‍ (as demonstrated in the Z0011 and SENOMAC trials) Patients⁢ with no palpable nodes and tumors 5cm or less are candidates ⁢for upfront surgery and sentinel lymph node biopsy.

The overarching goal: ⁣ To use preoperative therapy (when appropriate, based‍ on subtype) to eradicate* nodal⁢ disease, allowing for less invasive axillary surgery (de-escalation) and avoiding complete lymph node dissection when possible.